New pill takes on tough breast cancer in first human trial
NCT ID NCT07581314
First seen May 15, 2026 · Last updated May 25, 2026 · Updated 2 times
Summary
This study tests an experimental oral drug called Zn-Telomir in people with advanced or metastatic triple-negative breast cancer that has worsened after other treatments. The trial has two parts: first, finding a safe dose, then checking if the drug can shrink tumors. About 76 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.